ERBB2 and ductal breast carcinoma in situ: A Phase II trial testing a single pre-operative dose of trastuzumab in women with HER2-positive DCIS demonstrated an immunologic response that was not associated with either a pathologic or proliferation-related response (see Table 2) (25).